Zelira Therapeutics Ltd has released a press release.
June 2022 Quarterly Activities Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Zelira Therapeutics Ltd. on 6ix
Story so far
Earlier from Zelira Therapeutics
- Zenivol receives formal BfArM approval in Germany
- Response to ASX Price Query
- Pause in Trading
- EDCDM Technology License Agreement Update
- Zenivol Longitudinal, RWD Trial in Insomnia Results
Later from Zelira Therapeutics
- Response to ASX Aware Query
- ZLDs Diabetic Nerve Pain Drug Trial Two-Thirds Enrolled
- September 2022 Quarterly Activities Report
- ZLD Completes Enrolment for Diabetic Nerve Pain Drug Trial
- Zelira receives $1.14 million cash R&D Tax Incentive
Follow Zelira Therapeutics into a list and get an email when it puts out news.
Follow Zelira Therapeutics